Associated Papers
ATAD2 drives melanoma growth and progression and inhibits ferroptosis.
Mari A et al.
Embo Reports, 2026
41331524 (PubMed )
Supplement: 44319_2025_660_MOESM1_ESM.pdf
Biological evaluation of a novel sorafenib analogue, t-CUPM.
Wecksler AT et al.
Cancer Chemotherapy and Pharmacology, 2015
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
Sen B et al.
Science Translational Medicine, 2012
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Bollag G et al.
Nature, 2010
20823850 (PubMed )
Supplement: NIHMS233087-supplement-1.doc
Select a paper to view details